The new patent entitled, ‘Inhibitors of Serine Protease Activity and Their Use in Methods and Compositions for Treatment of Bacterial Infections,’ covers inhibition of all forms of Bacillus anthracis infection (commonly known as anthrax) using one or more of four new peptides made up of 10 linked amino acids.
Omni Bio Pharma said that the new patent is part of the technology licensed to Omni Bio through one of its technology license agreements with the University of Colorado Denver (UCD).
Omni Bio Pharma acting CEO Charles Dinarello said that the issuance of this patent by the USPTO expands their proprietary technology platform and is an important milestone in developing therapies to address potentially large and underserved markets.
"The focus of this patent demonstrates that AAT and AAT related peptides may have the potential to address a variety of indications, such as the prevention and treatment of anthrax infection, and may open proprietary channels of opportunity for the development of new therapeutics and preventatives in a variety of areas including bacterial infection and biohazards," Dinarello said.